For the past decade, fusion, cage or not, has been the gold standard in spine surgery. Now, a handful of companies, including Seattle-based Spinal Dynamics, is betting that fusion will be replaced by joint replacement, in this case artificial disc replacement, in spine surgery just as it did in total hip and knee surgery many years ago. Spinal Dynamics' main challenge lies in overcoming surgeon skepticism, especially in cervical procedures where fusions are common and very successful. And to help, they've lined up a distribution agreement with spine market leader Medtronic Sofamor Danek.
by David Cassak
As we noted last month, spine instruments and implants are the orthopedic industry's version of a 20-year overnight success. Today,...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.
J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.
A German biotech has solved a fundamental physics problem that has limited mRNA therapeutics to injectable vaccines. Its breakthrough stabilizer technology allows mRNA particles to survive the mechanical stress of inhalation delivery, opening the door to treating chronic respiratory diseases.
CEO Judy Chou brings big pharma experience to tackle chronic inflammation with the company's first-in-class PSGL-1 targeting therapy.
An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.
Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.
Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.
